Reply to Eschenauer et al

Clin Infect Dis. 2015 Feb 15;60(4):671-2. doi: 10.1093/cid/ciu885. Epub 2014 Nov 3.

Authors

Ravina Kullar¹, James A McKinnell², George Sakoulas³

Affiliations

¹ Department of Medical Affairs, Cubist Pharmaceuticals, Lexington, Massachusetts.
² Infectious Disease Clinical Outcomes Unit, Los Angeles Biomedical Research Institute, David Geffen School of Medicine, University of California Torrance Memorial Medical Center, California.
³ Division of Pediatric Pharmacology and Drug Discovery, University of California, San Diego School of Medicine, La Jolla.

No abstract available

Publication types

Letter
Comment

MeSH terms

Animals
Anti-Bacterial Agents / therapeutic use*
Bacteremia*
Humans
Methicillin-Resistant Staphylococcus aureus*
Staphylococcal Infections / drug therapy*

Substances

Anti-Bacterial Agents

Grants and funding

KL2 TR000122/TR/NCATS NIH HHS/United States